CIK 0001738021 · Non-accelerated filer<br>Smaller reporting company
Compass Therapeutics, Inc.
Sign in to watch- Ticker
- CMPX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-500-8099
- Business address
- 80 GUEST STREET, BOSTON, MA, 02135
- Former names
- Olivia Ventures, Inc.
- Open-market buys, last 90 days
- $21,250
- in 2 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$21,250. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-08 | Schuetz Thomas J. CEO | Shares withheld for taxes | −41,687 | $3.50 | $146K | 6,470,825 |
| 2025-01-09 | Schuetz Thomas J. CEO | Shares withheld for taxes | −58,054 | $1.86 | $108K | 6,512,512 |
| 2024-12-09 | Shin Barry CFO | Grant or award | +400,000 | $1.65 | $660K | 400,000 |
| 2024-12-09 | Shin Barry CFO | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2024-08-13 | Anderman Jonathan Sr VP, Gen Counsel & Corp Sec | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2024-03-08 | Boylan James P Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-02-09 | GRAY MARY ANN Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-02-09 | LINDAHL RICHARD S Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-02-09 | GORDON CARL L Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-02-09 | Chiniara Ellen Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-02-09 | Ferneau Philip Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-02-08 | Bisker-Leib Vered CHIEF EXECUTIVE OFFICER | Shares withheld for taxes | −49,198 | $1.45 | $71K | 3,124,426 |
| 2024-02-08 | Schuetz Thomas J. PRESIDENT | Shares withheld for taxes | −44,782 | $1.45 | $65K | 6,570,566 |
| 2024-01-09 | Bisker-Leib Vered Chief Executive Officer | Grant or award | +1,753,125 | $1.93 | $3.4M | 3,173,624 |
| 2024-01-09 | Bisker-Leib Vered Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +1,753,125 | 1,753,125 | ||
| 2024-01-09 | Schuetz Thomas J. President of R&D | Grant or award | +637,500 | $1.93 | $1.2M | 6,615,348 |
| 2024-01-09 | Schuetz Thomas J. President of R&D | Grant or award · Stock Option (Right to Buy) | +637,500 | 637,500 | ||
| 2023-11-17 | Bisker-Leib Vered Chief Operating Officer | Shares withheld for taxes | −64,415 | $1.50 | $97K | 1,420,499 |
| 2023-11-17 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER | Shares withheld for taxes | −44,025 | $1.50 | $66K | 5,977,848 |
| 2023-04-21 | LINDAHL RICHARD S Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 |
Page 3 of 8 · 143 trades